Clovis Oncology Shares Double on Trial Data for Cancer Drugs
This article is for subscribers only.
Clovis Oncology Inc. shares doubled today after the biotechnology company reported positive early results in trials of its lung and ovarian cancer drugs.
The shares jumped $38.01 to $74.59 at the 4 p.m. close in New York, the biggest one-day rise since the stock began trading in November 2011.